CT fractional flow reserve was associated with major adverse cardiac events in candidates for transcatheter aortic valve replacement and improved the predictive value of coronary CT angiography ass... Background The role of CT angiography–derived fractional flow reserve (CT-FFR) in pre–transcatheter aortic valve replacement (TAVR) assessment is uncertain. Purpose To evaluate the predictive value...
Objectives: We aimed to validate and test a prototype algorithm for automated dual-energy computed tomography (DECT)-based myocardial extracellular volume (ECV) assessment in patients with various cardiomyopathies. Methods: This retrospective study included healthy subjects (n=9; 61±10 y) and patients with cardiomyopathy (n=109, including a validation cohort n=60; 68±9 y; and a test cohort n=49; 69±11 y), who had previously undergone cardiac DECT. Myocardial ECV was calculated using a prototype-based fully automated algorithm and compared with manual assessment. Receiver-operating characteristic analysis was performed to test the algorithm’s ability to distinguish healthy subjects and patients with cardiomyopathy. Results: The fully automated method led to a significant reduction of postprocessing time compared with manual assessment (2.2±0.4 min and 9.4±0.7 min, respectively, P<0.001). There was no significant difference in ECV between the automated and manual methods (P=0.088). The automated method showed moderate correlation and agreement with the manual technique (r=0.68, intraclass correlation coefficient=0.66). ECV was significantly higher in patients with cardiomyopathy compared with healthy subjects, regardless of the method used (P<0.001). In the test cohort, the automated method yielded an area under the curve of 0.98 for identifying patients with cardiomyopathies. Conclusion: Automated ECV estimation based on DECT showed moderate agreement with the manual method and matched with previously reported ECV values for healthy volunteers and patients with cardiomyopathy. The automatically derived ECV demonstrated an excellent diagnostic performance to discriminate between healthy and diseased myocardium, suggesting that it could be an effective initial screening tool while significantly reducing the time of assessment.
Determination of the total number and size of all pulmonary metastases on chest CT is time-consuming and as such has been understudied as an independent metric for disease assessment. A novel artificial intelligence (AI) model may allow for automated detection, size determination, and quantification of the number of pulmonary metastases on chest CT. To investigate the utility of a novel AI program applied to initial staging chest CT in breast cancer patients in risk assessment of mortality and survival. Retrospective imaging data from a cohort of 226 subjects with breast cancer was assessed by the novel AI program and the results validated by blinded readers. Mean clinical follow-up was 2.5 years for outcomes including cancer-related death and development of extrapulmonary metastatic disease. AI measurements including total number of pulmonary metastases and maximum nodule size were assessed by Cox-proportional hazard modeling and adjusted survival. 752 lung nodules were identified by the AI program, 689 of which were identified in 168 subjects having confirmed lung metastases (Lmet+) and 63 were identified in 58 subjects without confirmed lung metastases (Lmet-). When compared to the reader assessment, AI had a per-patient sensitivity, specificity, PPV and NPV of 0.952, 0.639, 0.878, and 0.830. Mortality in the Lmet + group was four times greater compared to the Lmet-group (p = 0.002). In a multivariate analysis, total lung nodule count by AI had a high correlation with overall mortality (OR 1.11 (range 1.07–1.15), p < 0.001) with an AUC of 0.811 (R2 = 0.226, p < 0.0001). When total lung nodule count and maximum nodule diameter were combined there was an AUC of 0.826 (R2 = 0.243, p < 0.001). Automated AI-based detection of lung metastases in breast cancer patients at initial staging chest CT performed well at identifying pulmonary metastases and demonstrated strong correlation between the total number and maximum size of lung metastases with future mortality. As a component of precision medicine, AI-based measurements at the time of initial staging may improve prediction of which breast cancer patients will have negative future outcomes.